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2Abstract
Chronic unilateral hemisection (HX) of the adult rat spinal cord diminishes conduction
through intact fibers in the ventrolateral funiculus (VLF) contralateral to HX. Intraspinal
injections of Chondroitinase-ABC, known to digest chondroitin sulfate proteoglycans
(CSPGs) in the vicinity of injury, prevented this decline of axonal conduction. This was
associated with improved locomotor function. We further injected three purified CSPGs
into the lateral column of the uninjured cord at T10: NG2 and neurocan, which increase
in the vicinity of a spinal injury, and aggrecan, which decreases. Intraspinal injection of
NG2 acutely depressed axonal conduction through the injection region in a dose
dependent manner. Similar injections of saline, aggrecan, or neurocan had no significant
effect. These results identify a novel acute action of CSPGs on axonal conduction in
spinal cord, and suggest that antagonism of proteoglycans reverses or prevents the
decline of axonal conduction, in addition to stimulating axonal growth.
Key words: NG2, aggrecan, neurocan, Chondroitinase-ABC, node of Ranvier,
EPSP, TTX, CNQX.
3The accumulation of chondroitin sulfate proteoglycans (CSPGs) in and around the
glialscar is a major obstacle for recovery after spinal cord injury (SCI) (1, 2). CSPGs
consist of a core protein to which is attached one or more chondroitin sulfate
glycosaminoglycan side-chains. CSPGs are involved in a variety of CNS functions,
including the modulation of cell adhesion, cell migration, axonal outgrowth and synapse
formation (3-7). CSPGs are found diffusely in the extracellular matrix throughout the
CNS in the undamaged adult CNS, but also in a condensed matrix around neurons as
perineuronal nets and in similar structures at nodes of Ranvier (8, 9). The accumulation
of CSPGs in and around injury sites, particularly during the acute phase of injury, is
thought to be a major barrier for axonal regeneration in the adult mammalian spinal cord
and thus recovery of function after SCI (10-12). Degrading CSPGs by enzymatic removal
of chondroitin sulfate chains with the the chondroitin sulphate glycosaminoglycan
digensting bacterial enzyme chondroitinase-ABC (Ch’ase) promotes axonal regeneration
and stimulates anatomical plasticity in the damaged and undamaged brain and spinal cord
and encourages functional recovery (9, 13-17). Chondroitinase ABC treatment opens a
window of opportunity for task-specific rehabilitation (18). Many patients with partial
spinal cord injuries and preserved axons may nevertheless have no descending motor or
ascending sensory function below the injury, and various factors including demyelination
and inflammation have been proposed to explain the lack of conduction in surviving
axons (19).
Recently we found that a lateral hemisection lesion (HX) of the adult rat spinal cord
induces failure of axonal conduction through the intact axons contralateral to the HX,
beginning 1 week after injury and persisting for at least 14 weeks (20). The initiation of
4these physiological deficits coincided with the time that the elevated level of CSPGs in
tissue surrounding the HX reached its peak (21). A similar time schedule for CSPG
accumulation around the injury site has been reported in other SCI models (2, 10-12, 22).
The goal of this study was to determine if the elevated level of CSPGs surrounding a
spinal cord HX might be involved in the failure of axonal conduction in undamaged
axons on the other side of the cord. In order to answer this question we designed two sets
of experiments. Set 1 was directed towards evaluation of the ability of CSPG degradation
to restore axonal conduction that normally declines contralateral to hemisection. These
rats received a HX at thoracic T10 level; followed by immediate perilesional intraspinal
injection of Ch’ase, or the neutral bacterial enzyme penicillinase (P’ase) as control.
Following 4 weeks of behavioral testing one subgroup was used for electrophysiological
evaluation of transmission through the HX level to motoneurons below the HX; the other
subgroup was injected with an anatomical tracer to evaluate the survival of reticulospinal
axons. Set 2 was designed to test the effects of CSPGs on axonal conduction in the intact
spinal cord. Intact rats received intraspinal injections of purified CSPGs into the thoracic
lateral column or around the lumbar motoneurons in uninjured cords. The acute effect of
these injections on axonal conduction and on monosynaptic transmission to individual
lumbar motoneurons were measured.
Our results demonstrate that the post-injury conduction block in axons close to the lesion
can be prevented by Ch’ase infusion, and that NG2, one of the CSPGs upregulated after
injury, can block axonal conduction and transmission to motoneurons. Some of these
results have been reported in abstract form (23).
5Results.
1. Conduction failure in surviving axons after chronic hemisection can be prevented by
Ch’ase infusion.
1a. Acute hemisection does not affect conduction in contralateral axons.
We carried out simultaneous in-vivo intracellular recordings in the right L5 ventral horn
of the monosynaptic EPSP in motoneurons recorded intracellularly, and field potentials
recorded extracellularly, both in response to electrical stimulation of ipsilateral thoracic
VLF at T7. These responses were measured before and immediately (within 10 minutes)
after lateral HX of the left thoracic cord at T10 level. In uninjured rats, the peak
amplitude of the maximum monosynaptic EPSP (intracellular) was 5.2 ± 0.7 mV. The
extracellular response (extracellular) consisted of 2-3 peaks; an early biphasic
component, representing the volley of action potentials (measured between the arrows,
Fig. 1b), averaged 0.27 ±0.1 mV; the later component, representing the synaptic
response, averaged 0.3 ± 0.1 mV (n = 5). After the contralateral left thoracic cord was
hemisected at T10, the peak amplitude of these responses (4.6 ± 0.8 mV intracellular,
0.25 ± 0.1 mV early extracellular, 0.26 ± 0.2 mV later extracellular) were not
significantly different from those measured prior to acute HX (p=0.1, n = 5, Figs. 1a, b).
These results are consistent with the results of our recent study that demonstrated no
significant effect of acute HX on the responses from contralateral VLF above the
hemisection to motoneurons on the same side below the level of the hemisection (20).
1b. Chronic hemisection leads to conduction block in contralateral axons.
6In a previous study we showed that spinal cord hemisection leads to a gradual onset of
conduction block in axons contralateral to the lesion, starting at 1-2 weeks and continuing
for at least 14 weeks (20). We repeated these experiments with the addition of a control
infusion of penicillinase (P’ase), a bacterial enzyme with no effect in mammals, delivered
to the spinal cord parenchyma on either side of the lesion at the time of operation (n=5).
After 4 weeks rats were assessed electrophysiologically by in vivo intracellular recording
from individual motoneurons and extracellular recording from the ventral horn at the
lumbar L5 segment (Fig. 1). In these rats we found a marked reduction of the action
potential volley and the synaptic responses evoked by stimulation of VLF above the HX
level and recorded below. The mean peak amplitude of each response recorded from
chronically hemisected and P’ase treated rats (Fig. 1 c, d; intracellular: EPSP peak
amplitude 0.7 ± 0.3 mV; extracellular early peak: 0.04 ± 0.02 mV; later peak 0.05 ± 0.02)
was significantly smaller compared to acutely hemisected rats (Fig. 1 a, b; p =< 0.001).
Similar responses measured from chronically hemisected rats treated with P’ase were not
significantly different from those recorded previously (20) in rats that received HX and
no treatment for 4 weeks prior recordings (p =0.1, n = 5).
1c. Intraspinal Ch’ase attenuates conduction block adjacent to chronic spinal
hemisection.
We next asked whether the decline in axonal conduction and synaptic responses that
developed during the course of chronic HX (20) would still be observed if intraspinal
injections of Ch’ase were administered at the time of HX. Immediately after HX, rats
were injected intraspinally with either P’ase (n = 8) or Ch’ase (n = 9), and allowed to
7survive for 4 weeks of behavioral assessment; they were then prepared for either
electrophysiological recordings (n=5-6) or anatomical tracing (n=3). All responses
measured from rats of the Ch’ase group (n = 5) were markedly larger compared to the
P’ase group [intracellular: EPSP peak amplitude 2.2 ± 0.4 mV Ch’ase (vs 0.7 ± 0.3 mV
P’ase), Fig. 1c, e; p=<0.001; extracellular early peak: 0.15 ±0.03 mV Ch’ase (vs 0.04 ±
0.02 mV P’ase), p=<0.001; later peak: 0.14 ± 0.04 mV Ch’ase (vs 0.05 ± 0.02 P’ase),
Fig. 1d, f; p = 0.01)]. Thus Ch’ase treatment either prevents or reverses the decline in
action potential conduction through VLF white matter contralateral to a chronic HX.
After completion of these recordings, rats were transcardially perfused, and 10 µm thick
Cresyl Violet stained cross-sections were cut for reconstruction of the injury site, as
previously described (20). We found that most injuries were uniform with a complete
lesion of the left side of the cord (with the exception of one case, which was excluded
from the analysis).
1d. Ch’ase has no effect on number (density) of unlesioned axons contralateral to
hemisection.
To determine whether the physiological effects of Ch’ase on the conduction of axons
contralateral to HX could be associated with the changes in number of reticulospinal
axons, the tracer BDA was injected in the right reticular formation, and longitudinal
sections were used to quantify the reticulospinal axons in the right white matter
contralateral to the injury (Fig. 2 a-g). We computed the ratio of the labeled axons
counted 1 cm above vs 1 cm below the HX in all consecutive sections for each rat. The
8injury minimally affected these axons, and no difference in the preservation of these
axons across the segment across from the injury was found between P’ase (n = 3) and
Ch’ase (n = 3) groups (Fig. 2d, p=0.4).
1e. Ch’ase treatment improves locomotor behavior.
The animal’s ground locomotion performance was evaluated using the open field BBB
score and gait analysis. Consistent with the previously described locomotor performance
of rats that received lateral HX of the thoracic cord and no treatment (20), the animals in
both the P’ase and the Ch’ase groups spontaneously recover locomotor function, but the
recovery process slows at about 2 weeks post-HX (i.e. the time point when the decline of
axonal conduction in unlesioned axons becomes blocked) (Fig. 2). The animals treated
with Ch’ase, however, showed better interlimb coordination in the Open Field (Fig. 2, h,
i). Consistent with enhanced motor performance and better body stability observed using
BBB, gait analyses revealed a more normal base of support of the hindlimbs in the
Ch’ase group (Fig. 2j).
In summary, the results of anatomical tracing suggest that Ch’ase did not alter the
survival of reticulospinal axons across the segment contralateral to chronic HX, but
electrophysiological data demonstrated that the treatment partly prevented loss of
conduction in these fibers. The rescue of axonal conduction, probably, accounts for the
improved locomotor performance in Ch’ase treated animals.
92. Acute effects of purified CSPGs on conduction and synaptic transmission in the
intact spinal cord.
The data presented above suggest that the post-lesion decline in conduction in the intact
VLF could be due to an accumulation of CSPGs around the lesion site. To test directly
whether increased levels of CSPGs alter axonal conduction and synaptic transmission, we
injected purified CSPGs into the intact spinal cord at T10 and recorded responses in the
L5 ventral horn elicited by stimulating VLF at T7. We compared responses obtained just
before and immediately after the injection.
2a. In-vivo intraspinal injections of known pharmacological agents induce the predicted
changes in both axonal conduction and postsynaptic potentials, recorded in-vivo from the
adult rat spinal cord.
In order to evaluate if intraspinal injection is an effective delivery method with
preservation of continuous long-lasting in-vivo electrophysiological recordings, we
injected the following control substances directly into the spinal cord: saline, CNQX (an
AMPA/kainate receptor blocker which selectively blocked the initial monosynaptic
response of motoneurons (24), or tetrodotoxin (TTX), an inhibitor of voltage-gated Na-
channels, known to diminish propagation of the action potential.
Injections of saline (1-3 µl) either in the L5 ventral horn close to the recording area, or in
the thoracic T10 lateral white matter, had no effect on the evoked EPSP (intracellular) or
composite responses (extracellular) (Suppl. Fig. 1, a and b). Intraspinal injections of
CNQX [0.8µl(injected volume)/200µM(concentration in pipette)] close to the recording
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area depressed the intracellularly recorded EPSP, about 4 minutes post-injection. In the
case of the composite extracellular responses, the CNQX injections depressed only the
later peak of the evoked response (denoted as synaptic component of response, see 20),
while the earlier peak (denoted as action potential volley, see 20) was not affected (Suppl.
Fig. 1, n = 3). At 5 minutes after injecting TTX (0.8µl /30µM) into T10 lateral white
matter, all responses recorded intracellularly and extracellularly at L5 in response to
stimulation at T7 were blocked (Suppl. Fig. 1, n = 5). These pharmacological
experiments confirm previous suggestions (20) that the earliest biphasic component of
the composite extracellular response represents the volley of action potentials, while the
later component represents action potentials from neurons around the recording site
activated transynaptically.
2b. Injection of NG2 in T10 white matter causes depression of EPSPs recorded from L5
motoneurons in response to stimulation of T7 VLF.
Intraspinal injections of NG2 into the T10 lateral white matter of uninjured rat (between
stimulating and recording electrodes (Fig. 3f) consistent with the level of chronic HX in
Ch’ase experiments (see Fig. 1) depressed the EPSP responses recorded intracellularly
from lumbar motoneurons in a time- and dose- dependent manner (Fig. 3 a, e). Injections
of NG2 at relatively low doses (0.8µl/0.1µg, n = 5 rats) had no significant action (Fig.
3e). Immediately after injection of NG2 at a higher dose (0.8µl/0.2µg, n = 7 rats), the
amplitude of the evoked EPSPs was not changed, suggesting that the injection procedure
did not damage conducting axons and the recording cells. However, 1.5-2.5 h after
injection of 0.2µg NG2 into the T10 white matter, the amplitude of the EPSPs recorded
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intracellularly from L5 motoneurons was significantly depressed (Fig. 3e; P=0.03).
Injection of the higher doses of NG2 (0.8 µl/0.8 g, n = 5 rats) into T10 induced a greater
depression of the evoked EPSPs in L5 motoneurons, and this depression occurred more
rapidly, i.e. all measured EPSP responses reached the lower steady level within about 30-
45 min after the injection (Fig. 3d, e).
2c. Injection of NG2 causes axonal conduction block.
The most likely explanation for the depression of EPSPs in L5 motoneurons induced by
intraspinal injections of NG2 between the recording and stimulating electrodes (Fig. 3 a,
b) is failure of the action potentials to conduct past the injection site. Therefore, in
addition to intracellular recordings we carried out simultaneous extracellular recordings
from the L5 ventral horn and measured the effects of intraspinal injections of NG2 on the
action potentials volley responses (Fig. 3 c, d). We found that NG2 injected into T10
white matter between the stimulating and recording electrodes induced conduction block,
which closely paralleled the changes in the amplitude of intracellular EPSPs described
above, with a similar pattern for the time and dose-dependent depression induced by NG2
(Fig. 3e).
2d. Effects of NG2 depended on the level of intraspinal injections vs position of the
stimulating electrode.
To demonstrate that NG2 injections were effective only at all points between the
stimulating and recording electrode but ineffective if placed outside the conduction path,
we injected NG2 either into L4-L5 (near the recording electrode positioned in L5), or into
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T7 (just rostral to stimulating electrode) (Fig. 4). Injections of NG2 (0.2µg, n = 5)
between the stimulating and the recording electrodes, but near the recording area (L5),
induced a similar degree of depression of intracellular EPSPs (48.0 ±10.8%, p=0.008)
and extracellular composite responses (70.0±13.9%, p=0.04), as detected in the case of
NG2 injections at T10 (Fig 4a; 4c). No effects were observed in response to injections of
NG2 at T7 (Fig. 4b; 4d). These results suggest that NG2 depresses conduction at the level
of the injections. This suggestion is supported by immunohistochemical results (Suppl.
Fig. 2) demonstrating that NG2 injected intraspinally into T10 remains localized to the
injection site. Injection of NG2 just above the stimulating electrode had no effect on the
size of the intracellular EPSPs, demonstrating that NG2 does not cause conduction block
by damaging axons.
2e. Injection of aggrecan or neurocan does not cause conduction block.
We next asked whether the ability to block conduction was a specific property of NG2 or
a general property of CSPGs that are present at CNS injury site. We performed
intraspinal injections of two other CSPGs, aggrecan and neurocan, into the spinal cord
and carried out similar experiments. In contrast to the inhibitory action of NG2 injected
in T10 between stimulating and recording electrodes (see Fig. 3f), similar intraspinal
injections of either aggrecan (0.8 µg, p=0.3, n = 5, Fig 5 a, b, e, f) or neurocan (0.8 µg, p
= 0.6, n = 4, Fig. 5 e, f) had no significant effect on the evoked responses, recorded either
intracellularly or extracellularly. In rats tested initially on one side with aggrecan with no
decline in conduction observed, subsequent injections of NG2 in the contralateral white
matter depressed the evoked responses on that side (Fig. 5 c, d; n = 3). These results
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suggest that the depression of axonal conduction is specific to NG2, but not other CSPGs
studied, i.e. aggrecan or neurocan.
Discussion.
The main finding of this study is that CSPGs, either upregulated after spinal cord injury
or directly injected, are able to block axonal conduction in unlesioned axons. We found
that administration of Ch’ase across from the injured region at the time of HX largely
prevented (or reversed) the decline of conduction that we observed after 4 weeks in
untreated preparations (20) or after injections of control P’ase (Fig. 1). We also found
that NG2, a proteoglycan known to be released into the zone of injury (1, 2), acutely
diminished impulse conduction (Fig. 3).
Chondroitinase injected into the CNS retains some activity for around 2 weeks (25), so
the treatment must have prevented the accumulation of glycanated CSPGs during the
period when conduction block is first seen and this action is sufficient to maintain axon
conduction even after the enzyme is no longer present.
In previous experiments, the improved neurological function shown by spinally injured
animals treated with Ch’ase has been ascribed to enhanced axon regeneration and
sprouting (11, 13, 15). In the present experiments Ch’ase treatment again led to improved
motor function, with enhanced locomotion, although Ch’ase did not alter the number of
surviving reticulospinal axons contralateral to the HX (Fig. 2). Lateral hemisection
injuries have not previously been treated with Ch’ase. The present results suggest that at
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least part of the functional recovery due to Ch’ase in this model may be due to improved
axonal conduction which enhances transmission to cells downstream of the injury level
during the chronic stage of HX injury (Fig. 1).
In order to elucidate the role of CSPGs on these changes in axonal conduction, and to
discover whether these effects are general to all CSPGs or specific to one, we injected
three purified CSPGs, NG2, aggrecan and neurocan into the lateral column of uninjured
thoracic cords. NG2 and neurocan are upregulated after spinal cord injury (1, 2), whereas
aggrecan exhibits complex changes (3, 26, 27). We found that intraspinal injection of
NG2 (0.2-0.8 µg) at T10 to intact spinal cords depressed conduction and both early
(action potential volley) and later (synaptic) components of evoked synaptic potentials
measured in motoneurons in the L5 segment (Fig. 3). Injections made around the
motoneurons at L5 caused a similar decline (Fig. 4). We also performed extracellular
recordings, which showed that injection of NG2 at T10 caused a failure of action
potential transmission past the injection site. Injections of NG2 rostral to the stimulating
electrode had no effect on transmission, demonstrating that the conduction block is not
due to diffuse axonal damage (Fig. 4). These results suggest that NG2 depresses
conduction at the level of the injections. This effect therefore mimics the block of axon
conduction that was observed contralateral to chronic spinal cord hemisection. In
contrast, aggrecan and neurocan had no significant effect on transmission of impulses
down the cord. In rats tested initially with aggrecan, subsequent contralateral injections of
NG2 still depressed the evoked responses.
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The depression of the action potential volley strongly suggests that the depression of
synaptic responses might be a result of conduction block at the level of NG2 injection.
CPSGs have not previously been implicated in axonal conduction block. How might such
a block come about? Failure of conduction in large myelinated axons, such as the
reticulospinal axons that form monosynaptic connections to motoneurons, must
presumably indicate an event at the nodes of Ranvier, probably ultimately affecting the
function of voltage-gated sodium channels. Many nodes of Ranvier in the CNS are
contacted by an NG2 positive glial process and NG2 accumulates within the extracellular
matrix at peripheral nodes of Ranvier (28). Moreover, two other CSPGs are found at CNS
nodes, and appear to play a part in their construction (8, 29-31). The functions of NG2 as
well as that of other CSPGs found at nodes of Ranvier are unknown, but it is likely that
they participate in either the construction or stabilization of nodal specializations such as
the partitioning of ion channels into discrete structural domains. These questions require
further investigations.
Our results suggest that the decline of conduction induced by chronic hemisection is due
to upregulation of the CSPG NG2 around the injury site, and that this molecule in some
way affects nodes of Ranvier and their ability to conduct action potentials. These results
identify a new and diverse acute action of individual CSPGs on axonal conduction, and
carry potential for translational application to strengthen weak synaptic projections by
manipulating CSPGs to enhance conduction of surviving axons in the injured mammalian
spinal cord.
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Figure Legends:
Figure 1. Representative traces of EPSPs (intracellular) and evoked potentials
(extracellular) under the following conditions: a, b) after acute HX; c, d) chronic HX and
P’ase treatment; e, f) chronic HX and Ch’ase treatment. Insert to show position of
stimulation/recording electrodes vs HX. The extracellular responses consist of 2
components: the early biphasic arriving volley (measured between the arrows) and the
later downward extracellular synaptic response (measured from baseline to peak). Note
that P’ase did not reverse the effects of chronic hemisection in attenuating the
contralateral volley whereas Ch’ABC did partially attenuate it (see text).
Figure 2. Effects of Ch’ase on the number of surviving reticulospinal axons and
behavioral performance after chronic HX. (a-c) Longitudinal sections at the site of injury
showing the complete transection of the (a) dorso-lateral, (b) lateral and (c) ventral
funiculi of the left spinal cord and the preservation of the right white matter tracts. BDA
was injected in the right reticular formation of the animals and the reticulospinal axons
were counted in the right white matter contralateral to the injury, 1 cm above and below.
(d) Summary of results demonstrating no difference in the preservation of these axons
between the groups (p= 0.4). (e-g) Representative images of reticulospinal axons in the
contralateral white matter tracts (e) rostral to HX, (f) across from HX and (g) below the
HX. (h-j) The animal’s ground locomotion performance 42 days after operation: (h) right
hindlimb BBB score, (i) left hindlimb BBB score, and (j) base of support derived from
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gait analysis. Animals treated with Ch’ase showed better interlimb coordination. (*
P=0.02). Values are presented as mean ± s.e.m.
Figure 3. Effects of intraspinal NG2 injections in lateral T10 on the evoked EPSP
(intracellular), and the evoked composite potentials (extracellular). a) Superimposed
averaged responses: control EPSP (black), 5 min after NG2 injection (dotted red), 3 h
after NG2 injections (solid red). b) Summary of results demonstrating delayed depression
of evoked EPSPs after NG2. All means are peak amplitude of the responses from 7 rats,
and for each rat the response was an average of maximum responses recorded
intracellularly from 7 to 10 motoneurons before, 5 min after and 3 h after injections of
NG2 (0.2 µg). c) Evoked composite potentials in the same rat, under the same conditions
as in (a) to show depression of both action potential volley and synaptic components of
evoked response by 0.2 µg NG2. d) Higher dose of NG2 (0.8 µg) induces greater
depression of the action potential volley and synaptic components of evoked composite
responses; averaged responses recorded before (black) and 40 min after 0.8 µg NG2
injection (dark red). e) Summary of results demonstrating dose dependent action of NG2
on EPSPs (intracellular, red columns) and action potential volley (extracellular, green
columns). Ordinate represents mean ratio of the peak amplitudes of the maximum
responses from 5-7 rats (7 to 10 motoneurons in each rat) before and 3 h after NG2
injections at denoted doses. f) Diagram to show the position of the
stimulation/recording/injection electrodes. Symbol (*) above the brackets (b, e) represent
significant difference (p = 0.03) between the corresponding bars. Values are presented as
mean ± s.e.m.
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Figure 4. Injection of NG2 (0.2 µg) close to the recording electrode induced depression
of the evoked EPSPs (a, c, n = 4, p=0.008), to a similar extent as an injection of NG2 in
T10. Injection of NG2 at even higher doses (0.8 µg) rostral to the stimulation electrode
had no effect (b, d, n = 3). Values are presented as mean ± s.e.m.
Figure 5. Intraspinal injections of aggrecan or neurocan (both 0.8 µg; right T10) had no
effect on evoked EPSPs (intracellular), and no effect on the evoked composite potentials
(extracellular). a, b) Control response (black; position of recording/injection electrodes
on the right side, same as described for NG2 in Fig. 3f), 5 min after aggrecan injection
(dotted blue), 3 hour after aggrecan injections (solid blue). c, d) In rat initially injected
with aggrecan, subsequent contralateral injections of NG2 in contralateral white matter
(stimulate left T7, recorded from left L5, NG2 0.2 µg injected in left T10), depressed
both the EPSP (recorded intracellularly) and composite responses (recorded
extracellularly) (n = 3). e, f) Summary of results demonstrating no significant effect of
aggrecan and neurocan on the evoked EPSPs (intracellular) and action potential volley
(composite responses, extracellular) (see text for statistical analyses).
Supplementary Figure 1. Effects of intraspinal injections of control saline, CNQX and
TTX on the responses evoked by stimulation of ipsilateral VLF and recorded
intracellularly from a motoneurons (a) and extracellularly from the ventral horn (b). c)
Injection diagram. Note: injections of saline (either in lateral T10 or near recording
electrode in L5) had no effect; CNQX (injected near the recording electrode) blocked
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EPSPs (intracellular) and selectively blocked only later component of the evoked
response (extracellular); further injections of TTX (at T10) blocked all
components/responses.
Supplementary Figure 2. Appearance of the NG2 injection site: a) Localization of
endogenous and exogenous NG2 in the spinal cord, injection site; b) Normal appearing
white matter at contralateral side injected with ACSF, same animal. Images shown are Z-
stack projections of 6 images taken at 0.8m intervals. Bar=50 µm.
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Methods.
These studies were carried out on adult (~210 g) female Sprague-Dawley rats in
accordance with protocols approved by the Institutional Animal Care and Use Committee
at SUNY- Stony Brook and VAMC.
Surgical procedure for the lateral hemisection and intraspinal injections of Ch-ase at
thoracic level T10. Animals were deeply anesthetized with 3% isoflurane in 100% O2.
Dorsal laminectomy was performed to expose spinal cord segments T9-T11 and HX
performed as previously described (20). Briefly, one tip of the iridectomy scissors was
passed through the entire thickness of the spinal cord dorsal to ventral at the midline, and
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the left dorsal and ventral columns were cut from lateral to the midline. To assess the
effects of CSPG digestion, the rats received two intraspinal injections of either 1 µl of
100 U/ml protease-free Ch’ase (Seikagaku America, Falmouth, MA) or 1 µl of 100 U/ml
of the control enzyme P’ase (Sigma, St. Louis, MO) immediately after the lesion
procedure. Injections were given ipsilateral to the HX, 1 mm off the midline, 2 mm
rostral (first injection) and 2 mm caudal (second injection) to the HX, using a glass
micropipette (30 µm diameter, calibrated for a volume of 1 µl) attached to a 10 µl
Hamilton syringe connected to a microdrive, over a period of ten minutes/injection. In
each case, the tip of the injecting pipette was inserted 1 mm into the cord. The muscle
and skin were closed in layers, antibiotic (Baytril, 5mg/kg, 0.1 ml sc), analgesic
(Buprenorphine 5mg/kg, 0.1 ml sc), and 10 cc of sterile saline were administered
subcutaneously.
Behavioral assessment. Rats were allowed to move freely and were scored during a 4
minute period for their ability to use their hindlimbs by two independent blinded
observers. Joint movements, paw placement, weight support, and fore/hindlimb
coordination were judged according to the 21-point BBB locomotion scale (32). BBB
scoring was carried at day 4 and then at weekly intervals for 4 weeks. Additionally, the
hind-paws were inked, and the animals then walked along a track lined with paper,
allowing for the collection of footprints which were then used for the Gait Analysis (11).
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In vivo intracellular and extracellular recordings in damaged spinal cord. After
completing the behavioral evaluation, the rats dedicated for electrophysiological
experiments were used to detect the functional connections from uncut axons passing
through the region across from the HX. Rats were deeply anesthetized using a ketamine
(80 mg/kg, 0.5 ml) / xylazine (10 mg/kg, 0.5 ml) mixture i.p. Heart rate and expired CO2
were monitored continuously. Dorsal laminectomy of the spinal cord was performed with
two openings, at thoracic T6-T8 (for placement of the stimulation electrode) and lumbar
L1-L6 (for placement of recording electrodes at L5). We recorded the responses evoked
by VLF stimulation rostral/contralateral to HX intracellularly from L5 motoneurons and
extracellularly from the L5 ventral horn, below HX, (HX at left T10, recording from right
L5 motoneurons, stimulation of right T7 VLF).
Motoneurons were impaled with sharp glass microelectrodes (3M KAcetate; 50-70 M
resistance) and identified by their antidromic response to stimulation of the cut L5 right
ventral root. The resting membrane potential of motoneurons used for analysis ranged
from -45 to -65 mV.
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recording tungsten electrode was lowered into the lumbar L5 spinal cord to a depth of 1.3
mm. It was positioned to enter the cord at the dorsal root entry zone, at an angle of 20-
22O from vertical in the sagittal plane (tip directed rostrally).
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For electrical stimulation of VLF we used a tungsten electrode, inserted in the thoracic
cord on the same side as the recording electrodes. In order to determine an optimal depth
for the stimulating electrode, we monitored the evoked response from the extracellular
electrode while inserting the stimulation electrode. The depth of the VLF electrode from
which a maximum response was evoked was usually about 0.7-0.8 mm. The intensity to
evoke a maximum response usually ranged from 300-600 µA in chronically hemisected
cords and 40-100 µA in the intact cords. The VLF stimulus had duration of 50 µs and
was delivered at 0.1 Hz or 1Hz.
Tracing experiments to evaluate density of fibers that may form the stronger projections
in ChABC-treated spinal cord. The rats dedicated for anatomical study were anesthetized
as above and injected with the tracer BDA in the right reticular formation. After 14 days,
transcardical perfusion was carried out and a block of T5-L2 spinal segments was used to
prepare 20 µm thick longitudinal sections cut on a cryostat. Sections were processed as
previously described (11, 15) and BDA-traced reticulospinal axons were counted in the
right white matter contralateral to the injury. The number of labeled axons 1 cm caudal
and 1 cm rostral to the segment across from the HX was expressed as a ratio, and these
were compared between penicillinase and Ch’ase treated preparations using two way
ANOVA for statistical comparisons.
Immunocytochemistry and confocal microscopy to evaluate distribution of NG2 after it
intraspinal injections. Immunofluorescence staining of injected spinal cords with rabbit
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anti-NG2 (Chemicon) was carried out as described previously (33) and images were
taken on a Zeiss510 confocal microscope.
In vivo intracellular/extracellular recordings from the intact spinal cord and intraspinal
injections of CSPGs. Rats were anesthetized as above and dorsal laminectomy of the
spinal cord was performed with three openings, at thoracic T6-T8 (for placement of
stimulation electrode in T7), T10 (for placement of injection capillary) and lumbar L1-L6
(for placement of recording electrodes in L5). Intracellular and extracellular recordings
were performed as described above. After recording from 7-10 different motoneurons in
each spinal cord, while maintaining the last intracellular penetration, we injected CSPG
and continue to acquire intracellular EPSPs and extracellular evoked responses.
CSPGs, specifically the extracellular domain of NG2 (34), neurocan (Millipore) and
aggrecan (Sigma), were injected into the lateral column of thoracic cord, between
stimulation and recording sites (unless otherwise specified). For intraspinal injection we
used the same method as above. After injection of CSPGs, we usually recorded for 3
hours, and after that we recorded intracellularly EPSPs from 7-10 motoneurons again.
The maximum response for each cell was determined by examining responses to stimuli
of increasing intensity. Peak EPSP amplitude was measured from pre-stimulus baseline to
peak. Maximum responses from all motoneurons (50 consecutive responses/cell) were
averaged over all motoneurons recorded in each rat before and after CSPG injections,
respectively. For extracellular evoked responses, the average values of 500 consecutive
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responses were measured before and after CSPG injections and compared over all
animals.
We used the Axoprobe amplifier (Molecular Devices, Inc.) for intracellular recordings
and a Grass P5 amplifier (Grass Instruments, Inc.) for extracellular recordings. All
signals were digitized, stored on a PC and analyzed off line using PClamp 10. For
statistical data analyses we used one-way ANOVA (SigmaPlot 11.0). If significant
differences were observed between the groups, a Student-Newman-Keuls test was used
for pairwise multiple comparisons between them.
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